Financial Gravity Wealth Inc. bought a new stake in Zoetis Inc (NYSE:ZTS) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 922 shares of the company’s stock, valued at approximately $94,000.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Farmers & Merchants Trust Co of Chambersburg PA acquired a new stake in shares of Zoetis during the first quarter worth $25,000. Berman Capital Advisors LLC acquired a new stake in shares of Zoetis during the fourth quarter worth $26,000. Athena Capital Advisors LLC acquired a new stake in shares of Zoetis during the fourth quarter worth $29,000. Resources Investment Advisors Inc. acquired a new stake in shares of Zoetis during the fourth quarter worth $31,000. Finally, Lavaca Capital LLC acquired a new stake in shares of Zoetis during the fourth quarter worth $32,000. 90.84% of the stock is owned by institutional investors.
In other Zoetis news, insider Roxanne Lagano sold 2,000 shares of the business’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $101.89, for a total value of $203,780.00. Following the completion of the transaction, the insider now directly owns 30,727 shares of the company’s stock, valued at $3,130,774.03. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Clinton A. Jr. Lewis sold 6,124 shares of the business’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $101.60, for a total value of $622,198.40. Following the completion of the transaction, the executive vice president now directly owns 54,484 shares of the company’s stock, valued at $5,535,574.40. The disclosure for this sale can be found here. Over the last three months, insiders sold 410,333 shares of company stock valued at $38,674,547. Insiders own 0.29% of the company’s stock.
NYSE:ZTS opened at $99.03 on Monday. Zoetis Inc has a 1 year low of $77.00 and a 1 year high of $103.33. The company has a quick ratio of 2.46, a current ratio of 3.60 and a debt-to-equity ratio of 2.95. The stock has a market capitalization of $47.46 billion, a price-to-earnings ratio of 31.64, a price-to-earnings-growth ratio of 1.80 and a beta of 0.93.
Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 14th. The company reported $0.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.02. Zoetis had a return on equity of 73.85% and a net margin of 24.51%. The firm had revenue of $1.56 billion during the quarter, compared to analysts’ expectations of $1.53 billion. During the same period in the previous year, the firm earned $0.69 earnings per share. The company’s revenue was up 7.1% on a year-over-year basis. As a group, equities research analysts anticipate that Zoetis Inc will post 3.46 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, June 3rd. Shareholders of record on Thursday, April 18th will be paid a $0.164 dividend. The ex-dividend date is Wednesday, April 17th. This represents a $0.66 dividend on an annualized basis and a yield of 0.66%. Zoetis’s payout ratio is 21.09%.
A number of equities research analysts recently commented on ZTS shares. Zacks Investment Research cut Zoetis from a “hold” rating to a “sell” rating in a research note on Monday, February 4th. UBS Group started coverage on Zoetis in a research note on Wednesday, January 23rd. They set a “neutral” rating and a $86.00 price objective for the company. Stifel Nicolaus raised Zoetis from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $97.00 to $110.00 in a research note on Monday, March 4th. SunTrust Banks started coverage on Zoetis in a research note on Tuesday, March 19th. They set a “hold” rating and a $100.00 price objective for the company. Finally, BMO Capital Markets lifted their price objective on Zoetis from $93.00 to $101.00 and gave the stock a “market perform” rating in a research note on Monday, February 25th. Four analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $101.77.
ILLEGAL ACTIVITY WARNING: This news story was reported by Highlight Press and is the property of of Highlight Press. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://highlightpress.com/2019/04/22/financial-gravity-wealth-inc-acquires-shares-of-922-zoetis-inc-zts.html.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Read More: Bid-Ask Spread
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.